Anixa Biosciences Receives Patent Allowance for Breast Cancer Vaccine Technology in Korea

Anixa Biosciences has been granted a patent allowance in Korea for its breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. The patent covers vaccine adjuvants and formulations, providing composition and method claims for the treatment of breast cancer. This patent allows Anixa Biosciences to exclusively use this technology in Korea.